Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1427Carcinoma, Renal Cell 587Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 124Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 78Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 51Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 44Uterine Cervical Neoplasms 39Neuroblastoma 39Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Small Cell Lung Carcinoma 26Head and Neck Neoplasms 26

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Abdominal Neoplasms × Genitourinary × Clear all
NCT01316458 2017-06-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Novartis

Phase 2 Completed
51 enrolled
Genitourinary

Abdominal Neoplasms, Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡